NUS Professor Dean Ho Cuts Biological Age by 15 Years in Longevity Study

Professor Dean Ho, director of the Institute for Digital Medicine at the National University of Singapore, has reduced his biological age to 32 from his chronological age of 47, a 15-year reversal achieved through a two-year self-directed study. The DELTA study, published in the peer-reviewed journal PLOS One, tracked Ho’s response to lifestyle interventions including 20-hour daily fasts, 90-minute morning workouts, and Mediterranean-style nutrition. His metabolic switching speed improved from over 24 hours to 16.5 hours, and his resting heart rate dropped from 65 to 46 beats per minute.

How the study tracked biological aging in real time

The DELTA study, which began in mid-August 2024, departed from traditional annual health screenings by monitoring Ho’s physiology moment to moment. Ho wore three fitness trackers—a Whoop, Garmin, and Apple Watch—for eight months to capture continuous data on how his body responded to lifestyle changes. The research team introduced varying fasting durations, exercise routines, and nutrition adjustments while measuring real-time biological responses. This personalized approach revealed that biological age is not fixed but shifts based on stress, sleep, food, exercise, and illness.

The intensive regimen behind the 15-year reversal

Ho’s daily routine included approximately 20 hours of fasting, multiple 48-hour fasts, and 90 minutes of strength or cardiovascular training every morning. His diet centered on leafy greens, seeds, olive oil, lean protein, and other Mediterranean-style foods, with beverages limited to water, electrolytes, black coffee, and black tea without milk or sugar. The regimen produced measurable improvements: metabolic switching speed—how quickly the body shifts from burning sugar to fat—decreased from over 24 hours to 16.5 hours, significantly faster than the typical 36 to 72 hours for someone his age. His resting heart rate dropped from 65 to 46 beats per minute, indicating improved heart function and recovery.

Singapore’s emerging precision health market

Ho’s study aligns with broader momentum in Singapore’s precision health sector. Lucence Group, a precision health company founded in 2016 as a spin-off from A*Star, introduced the AgeQ biological age test about six weeks ago, the first built on an Asian cohort. The test, offered by private healthcare players including IHH Healthcare, measures blood biomarkers associated with healthy aging. According to research from the Singapore Longitudinal Ageing Studies, current smokers have a biological age 3.6 years older than non-smokers, while obese individuals are 4.2 years older than those with normal BMI. Frequent exercisers were 1.25 years younger, and high plant food intake correlated with one year less biological age.

Why biological age matters more than chronological age

Biological age measures how well the body functions, distinct from chronological age, which simply counts years lived. Ho’s research emphasizes that health is dynamic, not a static snapshot from annual screenings. Minister for Trade and Industry Tan See Leng noted at the August 11 AgeQ launch event that data-backed health assessment tools are an encouraging example of public-private collaboration bridging research and practical applications for healthier aging. As Lucence gathers more user data, the AgeQ test results will become increasingly precise, with the model refined over time.

Scrutiny and support around Ho’s extreme approach

Ho’s dramatic results have attracted both praise and skepticism. On social media, some observers questioned whether his improvements relied on performance-enhancing substances, though no evidence supports such claims. His spouse, Dr. Sarah Nami Ahn, defended Ho’s methodology on LinkedIn, stating he undertook the study partly to ensure he would be present for their two children if her health declined. She emphasized his commitment to using himself as a test subject for others’ benefit and described his approach as driven by genuine health improvement rather than vanity. The DELTA study remains ongoing, with Ho continuing to track his biological markers.

What this means for investors and health-tech companies

Ho’s findings boost the credibility of precision health as a market. Lucence Group and similar firms are positioning biological age testing as a preventive health tool that could reduce long-term healthcare costs by enabling early intervention. The Singapore government’s backing of the sector, combined with peer-reviewed publication of Ho’s results, signals institutional confidence in the field. However, investors should note that Ho’s results are from a single subject with an extreme regimen unlikely to be replicated by most users. The real value lies in whether the broader population can achieve measurable improvements through less intensive interventions.

Final Thoughts

Dean Ho’s 15-year biological age reversal demonstrates that personalized lifestyle interventions can produce measurable aging improvements, lending credibility to Singapore’s emerging precision health sector. For investors, the story validates demand for biological age testing, but results remain highly individual and dependent on adherence to rigorous protocols.

FAQs

Disclaimer:

The content shared by Meyka AI PTY LTD is solely for research and informational purposes.  Meyka is not a financial advisory service, and the information provided should not be considered investment or trading advice.